Published in Brief Bioinform on July 01, 2014
iGEMS: an integrated model for identification of alternative exon usage events. Nucleic Acids Res (2016) 0.77
MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma. Cancer Lett (2015) 0.77
Algorithms for differential splicing detection using exon arrays: a comparative assessment. BMC Genomics (2015) 0.75
Bioconductor: open software development for computational biology and bioinformatics. Genome Biol (2004) 143.19
Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol (2004) 101.91
Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics (2003) 100.88
Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci U S A (2001) 68.44
Prediction of complete gene structures in human genomic DNA. J Mol Biol (1997) 58.76
Alternative isoform regulation in human tissue transcriptomes. Nature (2008) 52.76
Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res (2003) 52.74
NCBI Reference Sequence (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res (2005) 37.39
Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet (2008) 24.51
Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem (2003) 21.11
Ensembl 2012. Nucleic Acids Res (2011) 14.55
BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis. Bioinformatics (2005) 9.84
GenBank. Nucleic Acids Res (2011) 8.85
Repeatability of published microarray gene expression analyses. Nat Genet (2008) 8.24
Reproducible research and Biostatistics. Biostatistics (2009) 6.42
Analysis of gene expression data using BRB-ArrayTools. Cancer Inform (2007) 6.09
genenames.org: the HGNC resources in 2011. Nucleic Acids Res (2010) 5.77
Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array. BMC Genomics (2006) 5.59
Discovery of tissue-specific exons using comprehensive human exon microarrays. Genome Biol (2007) 5.53
RNA processing and its regulation: global insights into biological networks. Nat Rev Genet (2010) 5.34
SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing. Cell (2008) 4.54
FIRMA: a method for detection of alternative splicing from exon array data. Bioinformatics (2008) 2.49
Microarrays: retracing steps. Nat Med (2007) 2.39
ANOSVA: a statistical method for detecting splice variation from expression data. Bioinformatics (2005) 1.88
Alternative splicing: global insights. FEBS J (2010) 1.76
Exon array data analysis using Affymetrix power tools and R statistical software. Brief Bioinform (2011) 1.53
Dissecting an alternative splicing analysis workflow for GeneChip Exon 1.0 ST Affymetrix arrays. BMC Genomics (2008) 1.25
Case studies in reproducibility. Brief Bioinform (2011) 1.18
Experimental comparison and evaluation of the Affymetrix exon and U133Plus2 GeneChip arrays. PLoS One (2007) 1.15
Probe-level estimation improves the detection of differential splicing in Affymetrix exon array studies. Genome Biol (2009) 1.10
Data analysis of alternative splicing microarrays. Drug Discov Today (2006) 1.00
MMBGX: a method for estimating expression at the isoform level and detecting differential splicing using whole-transcript Affymetrix arrays. Nucleic Acids Res (2009) 0.97
ARH: predicting splice variants from genome-wide data with modified entropy. Bioinformatics (2009) 0.95
Tumor-specific usage of alternative transcription start sites in colorectal cancer identified by genome-wide exon array analysis. BMC Genomics (2011) 0.94
Comprehensive analysis of alternative splicing and functionality in neuronal differentiation of P19 cells. PLoS One (2011) 0.88
REMAS: a new regression model to identify alternative splicing events from exon array data. BMC Bioinformatics (2009) 0.82
The dChip survival analysis module for microarray data. BMC Bioinformatics (2011) 0.80
Bayesian prediction of spatial count data using generalized linear mixed models. Biometrics (2002) 2.87
High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol (2003) 2.65
Normal linear models with genetically structured residual variance heterogeneity: a case study. Genet Res (2003) 2.63
FGFR3 dysregulation in multiple myeloma: frequency and prognostic relevance. Br J Haematol (2002) 2.07
Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol (2012) 1.93
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica (2014) 1.57
Evidence for genetic control of adult weight plasticity in the snail Helix aspersa. Genetics (2004) 1.31
Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica (2012) 1.21
Interrater reliability of diagnostic methods in traditional Indian ayurvedic medicine. Evid Based Complement Alternat Med (2013) 1.17
Reliability studies of diagnostic methods in Indian traditional Ayurveda medicine: An overview. J Ayurveda Integr Med (2013) 1.17
Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease. Eur Heart J (2006) 1.10
Role of routine imaging in detecting recurrent lymphoma: A review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma. Am J Hematol (2014) 1.01
The in vivo toxicity of hydroxyurea depends on its direct target catalase. J Biol Chem (2010) 0.99
In multiple myeloma clonotypic CD38- /CD19+ / CD27+ memory B cells recirculate through bone marrow, peripheral blood and lymph nodes. Leuk Lymphoma (2004) 0.97
Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma. Ann Hematol (2005) 0.97
Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs. Haematologica (2011) 0.96
Selection for environmental variation: a statistical analysis and power calculations to detect response. Genetics (2008) 0.95
Loss of MicroRNA targets in the 3' untranslated region as a mechanism of retroviral insertional activation of growth factor independence 1. J Virol (2009) 0.92
Generation of a predictive melphalan resistance index by drug screen of B-cell cancer cell lines. PLoS One (2011) 0.90
Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood (2003) 0.90
Neutrophil Extracellular Traps in Ulcerative Colitis: A Proteome Analysis of Intestinal Biopsies. Inflamm Bowel Dis (2015) 0.89
Multiparametric flow cytometry profiling of neoplastic plasma cells in multiple myeloma. Cytometry B Clin Cytom (2010) 0.88
Decomposition of Variance for Spatial Cox Processes. Scand Stat Theory Appl (2013) 0.88
Multiplex reverse transcription polymerase chain reaction screening in acute myeloid leukemia detects cytogenetically unrevealed abnormalities of prognostic significance. Haematologica (2005) 0.88
MyelomA Genetics International Consortium. Leuk Lymphoma (2012) 0.86
Cancer stem cells and the cellular hierarchy in haematological malignancies. Eur J Cancer (2009) 0.84
Anemia and erythropoiesis-stimulating agent administration in patients with non-Hodgkin lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone ± rituximab chemotherapy: results from an observational study. Leuk Lymphoma (2011) 0.84
Identification of ID-1 as a potential target gene of MMSET in multiple myeloma. Br J Haematol (2005) 0.82
Efficacy and safety of CD34-selected and CD19-depleted autografting in multiple myeloma patients: a pilot study. Exp Hematol (2002) 0.82
CRP genotype and haplotype associations with serum C-reactive protein level and DAS28 in untreated early rheumatoid arthritis patients. Arthritis Res Ther (2014) 0.81
Non-synonymous polymorphisms in the FCN1 gene determine ligand-binding ability and serum levels of M-ficolin. PLoS One (2012) 0.81
Exposure time independent summary statistics for assessment of drug dependent cell line growth inhibition. BMC Bioinformatics (2014) 0.81
C-MAF oncogene dysregulation in multiple myeloma: frequency and biological relevance. Leuk Lymphoma (2003) 0.80
MicroRNAs as novel biomarkers in diffuse large B-cell lymphoma--a systematic review. Dan Med J (2015) 0.79
Stable phenotype of B-cell subsets following cryopreservation and thawing of normal human lymphocytes stored in a tissue biobank. Cytometry B Clin Cytom (2014) 0.78
Polymorphisms in the MASP1 gene are associated with serum levels of MASP-1, MASP-3, and MAp44. PLoS One (2013) 0.77
Clinical impact of leukemic blast heterogeneity at diagnosis in cytogenetic intermediate-risk acute myeloid leukemia. Cytometry B Clin Cytom (2012) 0.77
Impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography staging in newly diagnosed classical Hodgkin lymphoma: fewer cases with stage I disease and more with skeletal involvement. Leuk Lymphoma (2014) 0.77
Treatment of Aggressive NK-Cell Leukemia: A Case Report and Review of the Literature. Case Rep Hematol (2011) 0.77
Cell of origin associated classification of B-cell malignancies by gene signatures of the normal B-cell hierarchy. Leuk Lymphoma (2013) 0.77
Validation and implementation of a method for microarray gene expression profiling of minor B-cell subpopulations in man. BMC Immunol (2014) 0.76
The CD19 compartment in myeloma includes a population of clonal cells persistent after high-dose treatment. Leuk Lymphoma (2002) 0.76
Gene expression profiling of murine T-cell lymphoblastic lymphoma identifies deregulation of S-phase initiating genes. Leuk Res (2013) 0.76
Bone Marrow Aspiration: A Randomized Controlled Trial Assessing the Quality of Bone Marrow Specimens Using Slow and Rapid Aspiration Techniques and Evaluating Pain Intensity. Acta Haematol (2015) 0.76
Disease risk estimation by combining case-control data with aggregated information on the population at risk. Biometrics (2014) 0.75
FGFR3 dysregulation and clinical outcome in myeloma. Br J Haematol (2003) 0.75
A model system for assessing and comparing the ability of exon microarray and tag sequencing to detect genes specific for malignant B-cells. BMC Genomics (2012) 0.75
[Cancer stem cells in the haematopoietic system]. Ugeskr Laeger (2010) 0.75
Alternative pre-mRNA splicing leads to potential biomarkers in diffuse large B-cell lymphoma - a systematic review. Dan Med J (2016) 0.75
A population-based study of prognosis in advanced stage follicular lymphoma managed by watch and wait. Br J Haematol (2015) 0.75
[Use of translational database at clinical department]. Ugeskr Laeger (2010) 0.75
[Mesenchymal stem cell therapy--the key to regenerative medicine?]. Ugeskr Laeger (2003) 0.75
[Acute lymphoblastic leukaemia in Danish children and young people 10 to 19 years of age. Should young adults with acute lymphoblastic leukaemia be treated in the same way as children?]. Ugeskr Laeger (2006) 0.75
[Complete remission after Rituximab treatment in refractory hairy cell leukemia]. Ugeskr Laeger (2008) 0.75
[The haematological biobank--an infrastructure for quality assurance, development and research]. Ugeskr Laeger (2011) 0.75
Prediction of haemorrhage in the early stage of acute myeloid leukaemia by flow cytometric analysis of platelet function. Br J Haematol (2005) 0.75